Table 1 Demographic and clinical characteristics of study groups
From: Colchicine treatment can be discontinued in a selected group of pediatric FMF patients
Characteristics | Group 1 N = 21 | Group 2 N = 30 | p value |
|---|---|---|---|
Male/female (n) | 10/11 | 17/13 | 0.5241 |
Age at disease onset | 4.14 ± 3.08 | 4.42 ± 3.74 | 0.7737 |
Family history of FMF (%) | 48 | 77 | 0.0327 |
Duration of colchicine treatment, years | 6.35 ± 2.76 | 5.69 ± 4.33 | 0.9958 |
Remission duration under colchicine treatment | 4.36 ± 2.12 | 2.53 ± 2 | 0.0036 |
Follow up duration off colchicine treatment, years | 4.52 ± 2.96 | 3.44 ± 3.27 | 0.2295 |
FMF attacks (%) | |||
Fever | 95 | 97 | 0.7959 |
Peritonitis | 76 | 90 | 0.1820 |
Arthritis | 33 | 70 | 0.0096 |
Pleuritis | 5 | 20 | 0.1196 |
ELE | 0 | 3 | 0.3981 |
Orchitis | 0 | 10 | 0.1352 |
Severe attacks a(%) | 24 | 80 | 0.000067 |
Non-attack manifestations (%) | |||
Exertional leg-pain | 10 | 50 | 0.0025 |
Treatment (%) | |||
Colchicine dose > 1 mg/day | 0 | 40 | 0.0009 |
Pras Score | |||
Pras SCORE | 7.14 ± 1.56 | 8.43 ± 1.57 | 0.0058 |
Pras SCORE ≥ 9 (%) | 19 | 43 | 0.0701 |